433 related articles for article (PubMed ID: 32728000)
1. The Clinical Efficacy of Endothelin Receptor Antagonists in Patients with Pulmonary Arterial Hypertension.
Maki H; Hara T; Tsuji M; Saito A; Minatsuki S; Inaba T; Amiya E; Hosoya Y; Hatano M; Morita H; Yao A; Kinugawa K; Komuro I
Int Heart J; 2020; 61(4):799-805. PubMed ID: 32728000
[TBL] [Abstract][Full Text] [Related]
2. Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension.
Fox B; Langleben D; Hirsch AM; Schlesinger RD; Eisenberg MJ; Joyal D; Blenkhorn F; Lesenko L
Can J Cardiol; 2013 Jun; 29(6):672-7. PubMed ID: 22819360
[TBL] [Abstract][Full Text] [Related]
3. What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis.
Li Q; Kuang HY; Wu YH; Lu TW; Yi QJ
Medicine (Baltimore); 2019 May; 98(20):e15632. PubMed ID: 31096477
[TBL] [Abstract][Full Text] [Related]
4. Safety and feasibility audit of a home-based drug-transitioning approach for patients with pulmonary arterial hypertension: an observational study.
Dawson A; Reddecliffe S; Coghlan C; Schreiber BE; Coghlan JG
Eur J Cardiovasc Nurs; 2018 Oct; 17(7):612-618. PubMed ID: 29641223
[TBL] [Abstract][Full Text] [Related]
5. Choice of Initial Oral Therapy for Pulmonary Arterial Hypertension: Age and Long-Term Survival.
Heresi GA; Love TE; Tonelli AR; Highland KB; Dweik RA
Am J Respir Crit Care Med; 2018 Oct; 198(8):1090-1093. PubMed ID: 29949380
[No Abstract] [Full Text] [Related]
6. Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
Grünig E; Ohnesorge J; Benjamin N; Burhenne J; Enderle Y; Egenlauf B; Fischer C; Harutyunova S; Huppertz A; Klose H; Haefeli WE
Respiration; 2017; 94(1):26-37. PubMed ID: 28494463
[TBL] [Abstract][Full Text] [Related]
7. A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.
Bedan M; Grimm D; Wehland M; Simonsen U; Infanger M; Krüger M
Basic Clin Pharmacol Toxicol; 2018 Aug; 123(2):103-113. PubMed ID: 29719121
[TBL] [Abstract][Full Text] [Related]
8. Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta-analysis.
Zhao Q; Guo N; Chen J; Parks D; Tian Z
J Clin Pharm Ther; 2022 Feb; 47(2):146-156. PubMed ID: 34319626
[TBL] [Abstract][Full Text] [Related]
9. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells.
Gatfield J; Mueller Grandjean C; Sasse T; Clozel M; Nayler O
PLoS One; 2012; 7(10):e47662. PubMed ID: 23077657
[TBL] [Abstract][Full Text] [Related]
10. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
Dranitsaris G; Mehta S
Appl Health Econ Health Policy; 2009; 7(1):43-59. PubMed ID: 19558194
[TBL] [Abstract][Full Text] [Related]
11. Evolution of Patients with Pulmonary Arterial Hypertension Starting Macitentan After the Discontinuation of Other Endothelin-Receptor Antagonists: Results of a Retrospective Study.
Cadenas-Menéndez S; Álvarez Vega P; Oterino Manzanas A; Alonso Lecue P; Roig Figueroa V; Bedate Díaz P; Ortiz de Saracho J; Cifrián Martínez JM
Am J Cardiovasc Drugs; 2020 Oct; 20(5):481-487. PubMed ID: 31879844
[TBL] [Abstract][Full Text] [Related]
12. Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study.
Escribano-Subias P; López R; Almenar L; Lázaro M; Forn I; Torrent A; Blanco I; Barberà JA;
BMC Pulm Med; 2020 Jun; 20(1):154. PubMed ID: 32487059
[TBL] [Abstract][Full Text] [Related]
13. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
Kabunga P; Coghlan G
Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488
[TBL] [Abstract][Full Text] [Related]
14. Endothelin inhibitors lower pulmonary vascular resistance and improve functional capacity in patients with Fontan circulation.
Agnoletti G; Gala S; Ferroni F; Bordese R; Appendini L; Pace Napoleone C; Bergamasco L
J Thorac Cardiovasc Surg; 2017 Jun; 153(6):1468-1475. PubMed ID: 28283234
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension: extended study results.
Aypar E; Alehan D; Karagöz T; Aykan H; Ertugrul İ
Cardiol Young; 2020 May; 30(5):681-685. PubMed ID: 32290885
[TBL] [Abstract][Full Text] [Related]
16. A review of pulmonary arterial hypertension: role of ambrisentan.
Barst RJ
Vasc Health Risk Manag; 2007; 3(1):11-22. PubMed ID: 17583171
[TBL] [Abstract][Full Text] [Related]
17. Functional estimation of endothelin-1 receptor antagonism by bosentan, macitentan and ambrisentan in human pulmonary and radial arteries in vitro.
Angus JA; Soeding PF; Hughes RJA; Wright CE
Eur J Pharmacol; 2017 Jun; 804():111-116. PubMed ID: 28300593
[TBL] [Abstract][Full Text] [Related]
18. Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension?
van Thor MCJ; Ten Klooster L; Snijder RJ; Kelder JC; Mager JJ; Post MC
Lung; 2019 Dec; 197(6):753-760. PubMed ID: 31583452
[TBL] [Abstract][Full Text] [Related]
19. A Bayesian Network Meta-analysis of Add-on Drug Therapies Specific for Pulmonary Arterial Hypertension.
Petrovič M; Locatelli I
Ann Pharmacother; 2020 May; 54(5):423-433. PubMed ID: 31735058
[No Abstract] [Full Text] [Related]
20. [Efficacy and safety of endothelin receptor antagonists combined with phosphodiesterase 5 inhibitor in the treatment of pulmonary arterial hypertension: a network meta-analysis].
Fu WH; Chen PL; Xia JL; Fu L; Shen Y; He WJ; Chen YH; Ren N; Jiang Q; Ma R; Wang T; Wang XN; Zhang NF; Liu CL
Zhonghua Jie He He Hu Xi Za Zhi; 2022 Feb; 45(2):158-170. PubMed ID: 35135085
[No Abstract] [Full Text] [Related]
[Next] [New Search]